FoxO1 signaling in B cell malignancies and its therapeutic targeting
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F25%3A00080525" target="_blank" >RIV/65269705:_____/25:00080525 - isvavai.cz</a>
Alternative codes found
RIV/00216224:14740/25:00140378
Result on the web
<a href="https://febs.onlinelibrary.wiley.com/doi/full/10.1002/1873-3468.15057" target="_blank" >https://febs.onlinelibrary.wiley.com/doi/full/10.1002/1873-3468.15057</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1002/1873-3468.15057" target="_blank" >10.1002/1873-3468.15057</a>
Alternative languages
Result language
angličtina
Original language name
FoxO1 signaling in B cell malignancies and its therapeutic targeting
Original language description
FoxO transcription factors (FoxO1, FoxO3a, FoxO4, FoxO6) are a highly evolutionary conserved subfamily of the 'forkhead' box proteins. They have traditionally been considered tumor suppressors, but FoxO1 also exhibits oncogenic properties. The complex nature of FoxO1 is illustrated by its various roles in B cell development and differentiation, immunoglobulin gene rearrangement and cell-surface B cell receptor (BCR) structure, DNA damage control, cell cycle regulation, and germinal center reaction. FoxO1 is tightly regulated at a transcriptional (STAT3, HEB, EBF, FoxOs) and post-transcriptional level (Akt, AMPK, CDK2, GSK3, IKKs, JNK, MAPK/Erk, SGK1, miRNA). In B cell malignancies, recurrent FoxO1 activating mutations (S22/T24) and aberrant nuclear export and activity have been described, underscoring the potential of its therapeutic inhibition. Here, we review FoxO1's roles across B cell and myeloid malignancies, namely acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), diffuse large B cell lymphoma (DLBCL), mantle cell lymphoma (MCL), Burkitt lymphoma (BL), Hodgkin lymphoma (HL), and multiple myeloma (MM). We also discuss preclinical evidence for FoxO1 targeting by currently available inhibitors (AS1708727, AS1842856, cpd10).
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
10610 - Biophysics
Result continuities
Project
Result was created during the realization of more than one project. More information in the Projects tab.
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2025
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
FEBS Letters
ISSN
0014-5793
e-ISSN
1873-3468
Volume of the periodical
599
Issue of the periodical within the volume
20
Country of publishing house
US - UNITED STATES
Number of pages
21
Pages from-to
2911-2931
UT code for WoS article
001357128900001
EID of the result in the Scopus database
2-s2.0-85208780933